Peripheral trigeminal nerve field stimulation

Report of 6 cases

ALBERTO FELETTI, M.D., PH.D.,1 GIANNANTONIO ZANATA SANTI, M.D.,1 FRANCESCO SAMMARTINO, M.D.,1 MARZIO BEVILACQUA, M.D.,2 PIERO CISOTTO, M.D.,1 AND PIERLUIGI LONGATTI, M.D.1

1Department of Neurosurgery, Treviso Hospital, University of Padova; and 2Department of Anaesthesiology, Pain Therapy Unit, Treviso Hospital, Treviso, Italy

Object. Peripheral nerve field stimulation has been successfully used for many neuropathic syndromes. However, it has been reported as a treatment for trigeminal neuropathic pain or persistent idiopathic facial pain only in the recent years.

Methods. The authors present a review of the literature and their own series of 6 patients who were treated with peripheral nerve stimulation for facial neuropathic pain, reporting excellent pain relief and subsequent better social relations and quality of life.

Results. On average, pain scores in these patients decreased from 10 to 2.7 on the visual analog scale during a 17-month follow-up (range 0–32 months). The authors also observed the ability to decrease trigeminal pain with occipital nerve stimulation, clinically confirming the previously reported existence of a close anatomical connection between the trigeminal and occipital nerves (trigeminocervical nucleus).

Conclusions. Peripheral nerve field stimulation of the trigeminal and occipital nerves is a safe and effective treatment for trigeminal neuropathic pain and persistent idiopathic facial pain, when patients are strictly selected and electrodes are correctly placed under the hyperalgesia strip at the periphery of the allodynia region.

(http://thejns.org/doi/abs/10.3171/2013.7.FOCUS13228)

Key Words • trigeminal neuropathic pain • persistent idiopathic facial pain • peripheral nerve field stimulation • trigeminocervical nucleus • hyperalgesia

Trigeminal neuropathic pain is a constant, burning, aching, or cramping facial pain, which can be associated with areas of partial sensory deficit.6 Its intensity can fluctuate, eventually leading to chronic pain. Herpetic infection and traumatic or surgical injury to the facial branches of the fifth cranial nerve are among the most frequent causes of TNP. Persistent idiopathic facial pain (previously called atypical facial pain) is defined as a persistent facial pain that does not have the characteristics of cranial neuralgias and cannot be attributed to a different disorder. It is limited to one particular area on one side of the face at disease onset, is deep and poorly localized, and is not associated with sensory loss or other neurological deficits, with no obvious structural abnormalities. Pain may be initiated by surgery or injury to the face, teeth, or gums, but it persists without any demonstrable local cause.8,10

First-line treatment includes anticonvulsant medications, baclofen, and opioids. Unfortunately, TNP and PIFP are often refractory to medical treatment. Moreover, patients frequently report side effects from medications as well as tolerance and dependence when opioid use is prolonged over time. Motor cortex stimulation and stereotactic trigeminal nucleotomy have been reported, with a success rate of 50%–70% of patients.16,20 More recently, PNS or PNFS have been used to treat TNP and PIFP, with promising results.3 We present a review of the literature about this technique (Table 1), adding our series of 6 patients (Table 2).
Case Reports

Case 1

This 22-year-old woman presented to our outpatient clinic with a 3-year history of left trigeminal neuralgia. The patient had undergone venous microvascular surgical decompression twice at another institution because of a misdiagnosis of typical trigeminal neuralgia. After surgery she still reported left facial pain, with thermal and mechanical static allodynia in the V1 and V2 territories, along with paresthesia and dysesthesia. Scar pain was also present in the territory of the greater and lesser occipital nerves, with left retroauricular hypesthesia. A left facial hemispasm induced frequent left eye blinking. Trigger points were detectable in the distribution of the V1 and V2 branches of the left trigeminal nerve and in the cephalic portion of the occipital scar. The patient reported 10/10 pain on the VAS at admission. Her life was severely affected by facial pain. She had lost her job and had dramatically reduced her social activities.

After a 14-day trial of PNFS in the supraorbital, infraorbital, and greater occipital nerves, the patient returned to the clinic and reported significant improvement in pain relief and quality of life. She subsequently underwent implantation of 1 Axxess quadripolar and 1 Quatrode quadripolar percutaneous lead in the left V1 and V2 regions, and 1 Octrode octopolar percutaneous lead in the occipital region that were connected to a rechargeable pulse generator (Eon Mini; all equipment obtained from St. Jude Medical), which was implanted in the left subaxillary subcutaneous space. The implanted stimulator was programmed with a pulse width of 300 μsec and a rate of 20 Hz. The patient obtained excellent pain control (2/10 on the VAS). Fifteen months after surgery, the patient is not reporting significant pain, is considerably reducing drug intake, has found a new job, and has improved her social relationships.

Case 2

This 58-year-old man was involved in a crash trauma of the neurocranium and the facial skeleton 15 years prior to presentation, with right eye enucleation. He reported chronic right-sided facial pain in the V1 distribution and a more severe right-sided pain in the region of the greater and lesser occipital nerves. Pain was rated 9/10 on the VAS and was poorly managed medically. On examination he had thermal and mechanical static allodynia of the right frontoparietal region. Transcutaneous electrical nerve stimulation was applied in the right occipital and parietotemporal regions with a rate of 80 Hz. Good pain control was obtained not only in the occipital region but also in the V1 distribution.

For this reason, after a 14-day trial of PNFS in the right greater occipital nerve he underwent implantation of 2 octopolar electrodes (Octad) that were connected to a Prime Advanced pulse generator (electrodes and pulse generator obtained from Medtronic, Inc.). The implanted stimulator was programmed with a pulse width of 450 μsec and a rate of 80 Hz, similarly to transcutaneous electrical nerve stimulation. Pain was successfully controlled, with a VAS score of 3/10 in both the occipital and V1 distributions. The patient reported an improvement of life quality. After a long period of unemployment, he found a job as a janitor, and he returned to his previous social activities. The system was removed 2 years later because of a foreign body giant cell–mediated granulomatous reaction, whose origin was not unquestionably defined. One year later, he underwent implantation of 2 octopolar percutaneous leads (St. Jude Medical) in the subcutaneous region of the greater and lesser occipital nerves; the leads were positioned mimicking a lotus flower shape to better cover the pain area (Fig. 1). Electrodes were connected to a rechargeable pulse generator (Eon Mini; St. Jude Medical), which was implanted in the right infraclavicular subcutaneous space. The implanted stimulator was programmed with a pulse width of 425 μsec and a rate of 70 Hz. The patient reported a significant decrease of pain (4/10 on the VAS), which was lasting as of the 32-month follow-up.

Case 3

This 41-year-old woman presented with a 4-year history of worsening pain in the V2 and V3 distribution bilaterally, with hypesthesia and paresthesia. Symptoms were more intense on the left side. The patient also reported impaired chewing movement. On examination she had thermal and mechanical static and dynamic allodynia. She reported a 10/10 pain on the VAS. The patient had been involved in a car accident 4 years prior to presentation to our clinic. She had multiple facial fractures, with right-sided LeFort 1, left-sided LeFort 1 and 2, inferior orbital rim, and nasal bone fractures, and detachment of several teeth. At that time, the fractures were stabilized with titanium plating, which had been removed 5 months later. During maxillofacial surgery, the surgeon described a laceration injury of the left infraorbital nerve. Severe facial pain appeared 4 months after the accident. Conservative treatments were not effective to reduce pain.
Peripheral trigeminal nerve field stimulation

Analgesic block of the left infraorbital nerve with local anesthetics was successful.

After a 16-day trial of PNFS in the left infraorbital nerve, she underwent implantation of a quadripolar percutaneous lead (Axxess; St. Jude Medical) in the left V2 region that was connected to a rechargeable pulse generator (Eon Mini; St. Jude Medical). The implanted stimulator was placed in the left subaxillary subcutaneous space and was programmed with a pulse width of 350 μsec and a rate of 16 Hz (Fig. 2). The patient reported a significant decrease of pain (VAS Score 0/10 on the left side and 5/10 on the right side). One year later she suffered a cervical spine trauma during a car collision. The electrode was distracted, with subsequent dysfunction. She underwent substitution of the electrode with a new Axxess quadripolar Quatrode percutaneous lead (St. Jude Medical). The pulse width was set at 300 μsec and a rate of 16 Hz. At the 19-month follow-up she was very satisfied by the implant. She had significantly reduced use of pain control medications. She went back to her job, and she reported better social relationships.

**Case 4**

This 54-year-old woman presented with a 7-year history of left trigeminal neuralgia of uncertain origin. She was treated with alcoholization of the gasserian ganglion at another institution. Unfortunately her pain worsened after the procedure. As a consequence of incorrect alcohol injection, ulcerations and trophic changes appeared on the left hemiface along with vasomotor dysfunction, which was consistent with a complex regional pain syndrome Type II (Fig. 3A and B). She underwent implantation of an electrode covering the V2 area at the same institution, which was removed early because of infection. At admission to our department, the patient reported left facial pain in V1, V2, and V3 (VAS Score 10/10). Alloodynia was prevalent in V2, and hyperalgesia was stronger in V3. At examination, dystrophic ulcerations covered the glabella, the left nasal ala, the left eyebrow, and the maxillary region. The patient was blind in the left eye, with no corneal reflex.

After a 14-day trial of PNFS in the V1, V2, and V3 regions, the patient underwent implantation of an octopolar electrode (Octad) in the left V3 region, and 2 quadripolar electrodes (Quad PISCES) in the left occipital and V2 regions that were connected to a pulse generator (Prime Advanced; all equipment obtained from Medtronic, Inc.), which was implanted in the left infraclavicular subcutaneous space (Fig. 3C). The implanted stimulator was programmed with a rate of 16 Hz. Pulse width was set at 210 μsec for V1, 350 μsec for V2, and 370 μsec for V3. The patient reported satisfactory pain relief (VAS Score 2/10). However, the system was removed 1 year later because of a Staphylococcus aureus infection that probably originated from her nasal septal ulcerations.

**Fig. 2.** Case 3. Frontal radiograph showing a quadripolar lead in the left V2 region.

**Fig. 3.** Case 4. This patient presented with ulcerations and trophic changes of the left hemiface after alcohol injection into the gasserian ganglion (A). Pain and ulcerations improved (B) after implantation of an octopolar electrode in the left V3 region and 2 quadripolar electrodes in the left occipital and V2 regions. Postoperative radiograph (C) showing the implanted electrodes.
**Case 5**

This 77-year-old woman presented with a 1-year history of postherpetic right trigeminal neuralgia in the V1 region. Standard medical treatments were not effective. The patient presented with V1 right trigeminal neuralgia (VAS Score 10/10). After the usual 14-day trial, the patient underwent implantation of 2 quadripolar electrodes (Quad PISCES) in the right V1 region, which were connected to a pulse generator (Prime Advanced; all equipment obtained from Medtronic, Inc.) that was implanted in the right infraclavicular subcutaneous space. The implanted stimulator was programmed with a pulse width of 450 μsec and a rate of 50 Hz. The patient reported satisfactory pain relief (VAS Score 3/10), which was confirmed at 2-year follow-up.

**Case 6**

This 67-year-old woman affected by rheumatoid arthritis presented with a long history of chronic facial pain in the V2 distribution of the right trigeminal nerve, rated 10/10 on the VAS. A trigger point was identified at the emergence of the infraorbital nerve, which elicited local disregulation of the autonomic somatosensory system. Analgesic block of the left infraorbital nerve with local anesthetics was successful. A 21-day trial of PNS in the infraorbital nerve was successful, with a reported pain of 3/10 on the VAS (Fig. 4).

**Discussion**

Although the potential to control neuropathic pain with PNS was discovered by Wall and Sweet in the 1960s, this system was not commonly used in clinical practice until the late 1990s. Increasing interest about the potential to control neuropathic pain with PNS and PNFS in recent years has led to a wider use of neurostimulation to control headache and pain in the extremities and in the occipital region. Manufacturing developments have made it possible to reduce the thickness of the electrodes, which can also be used in facial regions without any esthetic impairment. Analgesic block of the left infraorbital nerve with local anesthetics was useful in determining whether surgery is indicated. We applied the standard exclusion criteria that are also used for spinal cord stimulation. Long-term anticoagulant therapy, earlier pacemaker implant, alcohol abuse, current medicolegal issues, and inadequate family compliance contraindicate PNFS surgery. Psychiatric disturbances such as personality alterations, active psychosis, and major depression were ruled out by administering the Minnesota Multiphasic Personality Inventory–2 test to all of our patients. Analgesic block of the affected nerves with local anesthetics was also useful in determining whether surgery is indicated.

Our surgical technique is similar to those already published and is performed in 2 steps. Initially, electrodes are inserted for the stimulation trial after induction of local anesthesia. We routinely insert the electrodes through a 3-mm supraauricular (V1 electrodes) or preauricular (V2 and V3 electrodes) vertical incision. A 14-gauge Tuohy needle is used to advance 4- or 8-contact electrodes percutaneously through a plane between the subcutaneous and dermal spaces (Fig. 5). The aim is to place the electrode at the level of the hyperalgesia strip, which is at the periphery of the allodynia region. In our experience this target allows the best pain control. We present with constant, continuous symptoms. The pathophysiology of TNP and PIFP is still poorly understood. In these cases, treatment can be particularly challenging because pain is resistant to the commonly used medications, and microvascular decompression and peripheral neurotomy are generally ineffective. We found 29 cases of TNP/PIFP treated with PNFS in the literature (Table 1). Trauma and herpes zoster are the most common causes. The supraorbital nerve is the most frequent target for trigeminal neurostimulation (22 cases), followed by the infraorbital nerve (10 cases). Reported results are good in the majority of the patients, with a pain reduction of at least 50% in more than 80% of cases. Follow-up times range from 3 months to 4 years. Besides infection, complications are usually related to mechanical issues such as electrode dislocation.

Our series includes 6 patients who underwent implantation of electrodes for supraorbital nerve (2), infraorbital nerve (4), occipital nerve (3), and mandibular nerve (1). In 2 patients more than one nerve was stimulated. The average VAS score at admission was 10, whereas the average VAS score at the last follow-up was 2.7, confirming the high success rate of PNFS for TNP and PIFP (Table 2). Good outcome is dependent on correct patient selection.

![Fig. 4. Case 6. Frontal (A) and lateral (B) radiographs showing the placement of a quadripolar electrode in the right V2 region. Photograph (C) showing how the electrode (dotted lines) should be placed under the hyperalgesia strip (yellow), avoiding the allodynia region (red).](image-url)

*Neurosurg Focus / Volume 35 / September 2013*
Peripheral trigeminal nerve field stimulation

hypothesize that in this way the electrode might stimulate A-beta fibers, which are closer to the hyperactivated C-fibers in the hyperalgesia region. Further studies are required to verify this phenomenon.

Fluoroscopic guidance is used to verify the final position of the electrodes. The standard landmarks are used: the supraorbital foramen and ridge, the infraorbital foramen, and the inion. The patient is intraoperatively tested for paresthesias induced by electrode stimulation to confirm the correct positioning. When inserting the electrode, the area of allodynia shouldn’t be selected as the target area, because a complete deafferentation usually prevents any effect of PNFS or can even paradoxically enhance pain. Instead, the electrode should be positioned at the hyperalgesic peripheral area, where nerve connections are still present (Fig. 4C). We generally use a von Frey hair esthesiometer to map facial areas and identify both the allodynia region and the hyperalgesia strip. It is also advisable to avoid a position that is too close to the orbicularis oculi or the or-

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>No. of Pts</th>
<th>Age (yrs), Sex</th>
<th>Etiology</th>
<th>Area</th>
<th>Implant</th>
<th>FU</th>
<th>Outcome</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dunteman, 2002</td>
<td>2</td>
<td>86, M PH</td>
<td>lt V1, SON</td>
<td>3 yrs</td>
<td>improved</td>
<td>improved</td>
<td>battery exhaustion</td>
<td></td>
</tr>
<tr>
<td>Johnson &amp; Burchiel, 2004</td>
<td>10</td>
<td>39, F PT</td>
<td>rt V1, SON</td>
<td>2 yrs</td>
<td>70% of pts w/ &gt;50% pain relief</td>
<td>wound breakdown</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>86, M PH</td>
<td>rt V1, SON</td>
<td></td>
<td></td>
<td></td>
<td>none</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td></td>
<td>44, M PH</td>
<td>rt V1, SON</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>none</td>
<td></td>
</tr>
<tr>
<td></td>
<td>37, F AFP</td>
<td>lt V1, SON</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>wound breakdown</td>
<td></td>
</tr>
<tr>
<td></td>
<td>61, M PH</td>
<td>lt V1, SON</td>
<td></td>
<td></td>
<td></td>
<td>short extension cable</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td></td>
<td>41, M PT</td>
<td>rt V1, SON</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>none</td>
<td></td>
</tr>
<tr>
<td></td>
<td>83, F PH</td>
<td>lt V1, SON</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>none</td>
<td></td>
</tr>
<tr>
<td></td>
<td>53, M PT</td>
<td>lt V1, SON</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>none</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45, M PT</td>
<td>lt V2, ION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>none</td>
<td></td>
</tr>
<tr>
<td></td>
<td>33, M PT</td>
<td>rt V2, ION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>Slavin et al., 2006†</td>
<td>9</td>
<td>SON (4); ION (3);</td>
<td></td>
<td>35 mos</td>
<td>73% of pts w/ &gt;50% pain relief</td>
<td>none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yakovlev &amp; Resch, 2010</td>
<td>1</td>
<td>72, F AFP</td>
<td>lt V3, MN</td>
<td>12 mos</td>
<td></td>
<td>excellent</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>Stidd et al., 2012</td>
<td>3</td>
<td>71, M PT</td>
<td>lt V1, V2, SON + ION</td>
<td>27 mos</td>
<td>VAS score from 10 to 0</td>
<td>occasional HA when stimulator on &amp; no pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52, M PT</td>
<td>lt V1, V2, SON + ION (2 electrodes)</td>
<td>23 mos</td>
<td>VAS score from 8 to 0</td>
<td>none</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>44, M PH</td>
<td>rt V1, SON</td>
<td></td>
<td>6 mos</td>
<td>60% pain relief</td>
<td>dislocation of electrodes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asensio-Samper et al., 2008</td>
<td>1</td>
<td>34, M PT</td>
<td>rt V1, SON</td>
<td>4 yrs</td>
<td>VAS score from 10 to 2</td>
<td>battery exhaustion 4 yrs later</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reverberi et al., 2009</td>
<td>1</td>
<td>61, F ETN</td>
<td>rt V1, V2, SON + ION</td>
<td>5 mos</td>
<td>VAS score from 10 to 1</td>
<td>dislocation of ION electrode</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upadhyay et al., 2010</td>
<td>1</td>
<td>42, F PS</td>
<td>rt V1, V2, SON + ION</td>
<td>3 mos</td>
<td>&gt;50% pain relief</td>
<td>none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lenchig et al., 2012</td>
<td>1</td>
<td>42, F</td>
<td>rt V1, V2, SON</td>
<td>3 mos</td>
<td></td>
<td>none</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* AFP = atypical facial pain; ETN = essential trigeminal neuralgia; FU = follow-up; HA = headache; ION = infraorbital nerve; MN = mandibular nerve; ON = occipital nerve; PH = postherpetic; PS = postsurgical; PT = posttraumatic; pts = patients; SON = supraorbital nerve.
† Patients treated since 2000; data are the mean values referring to a wider series including occipital PNS.

TABLE 2: Patients treated with PNFS for TNP at Treviso Hospital

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yrs), Sex</th>
<th>Etiology</th>
<th>Pain Region</th>
<th>Implant</th>
<th>FU (mos)</th>
<th>VAS Preop</th>
<th>VAS Postop</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>22, F</td>
<td>PIFP</td>
<td>lt V1, V2, ON</td>
<td>SON, ION, ON</td>
<td>15</td>
<td>10</td>
<td>2</td>
<td>none</td>
</tr>
<tr>
<td>2</td>
<td>58, M</td>
<td>PT</td>
<td>rt V1, ON</td>
<td>ON</td>
<td>32</td>
<td>9</td>
<td>4</td>
<td>none</td>
</tr>
<tr>
<td>3</td>
<td>41, F</td>
<td>PT</td>
<td>rt V2, V3</td>
<td>ION</td>
<td>19</td>
<td>10</td>
<td>0 (lt), 5 (rt)</td>
<td>traumatic rupture</td>
</tr>
<tr>
<td>4</td>
<td>54, F</td>
<td>PS (chemical)</td>
<td>lt V1, V2, V3</td>
<td>ON, ION, MN</td>
<td>12</td>
<td>10</td>
<td>2</td>
<td>infection</td>
</tr>
<tr>
<td>5</td>
<td>77, F</td>
<td>PH</td>
<td>rt V1</td>
<td>SON</td>
<td>24</td>
<td>10</td>
<td>3</td>
<td>none</td>
</tr>
<tr>
<td>6</td>
<td>67, F</td>
<td>PIFP</td>
<td>rt V2</td>
<td>ION</td>
<td>1</td>
<td>10</td>
<td>3</td>
<td>none</td>
</tr>
</tbody>
</table>
reduce not only the major occipital pain, but also the trigeminal pain. We noticed a similar effect also for the patient in Case 1, in whom 3 electrodes were implanted—on the supraorbital nerve, infraorbital nerve, and occipital nerve—and who reported enhanced trigeminal pain control when the occipital electrode was also activated. This effect can be explained by the presence of close relations between the pars caudalis of the spinal nucleus of the trigeminal nerve and the dorsal horn of the spinal cord. Increasing the rate of stimulation to 70–80 Hz can also enhance the backward stimulating effect. It is important to be aware of these anatomical interrelations, because they might sometimes be useful to increase the PNFS-induced pain control in patients affected by trigeminal neuralgia.

**Conclusions**

Peripheral nerve field stimulation for TNP and PIFP has a significant success rate, improving pain relief, functional capacity, and quality of life. The surgical procedure is relatively easy. However, a strict patient selection process is mandatory to rule out other causes of trigeminal pain. A careful patient examination is required to identify the hyperalgesia strip close to the allodinia region. This is the target area where electrodes should be positioned. Sometimes patients report both occipital and trigeminal pain. In other patients trigeminal PNFS alone has an incomplete effect on facial pain control. In such cases occipital stimulation can either fully control trigeminal pain or significantly enhance the effects of electrodes placed in the trigeminal nerve distribution. This is probably due to the trigeminocervical complex activation.

**Disclosure**

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author contributions to the study and manuscript preparation include the following. Conception and design: Feletti, Zanata Santi. Acquisition of data: Sammartino. Analysis and interpretation of data: Feletti, Zanata Santi. Drafting the article: Feletti. Critically revising the article: Zanata Santi, Sammartino, Bevilacqua, Cisotto, Longatti. Reviewed submitted version of manuscript: Feletti, Zanata Santi, Sammartino, Longatti. Approved the final version of the manuscript on behalf of all authors: Feletti. Statistical analysis: Feletti. Study supervision: Bevilacqua, Cisotto, Longatti.

**References**

5. Dunteman E: Peripheral nerve stimulation for unremitting

---

**Fig. 5.** The head of a statue of Napoleon by Antonio Canova is used to show how the electrode is advanced to the infraorbital region through a 14-gauge Tuohy needle.
Peripheral trigeminal nerve field stimulation

ophthalmic postherpetic neuralgia. **Neuromodulation** 5:32–37, 2002

20. Piazza Ospedale 1, 31100 Treviso, Italy. email: alberto.feletti@gmail.com.